Josephine Volovetz

Josephine Volovetz

Auto-generated profile, based on publicly available information

Josephine Volovetz

Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JVJosephine Volovetz
Josephine Volovetz
LBLine V. Buchwald
Line V. Buchwald
KSKarina Straede
Karina Straede
Andreas KjaerAndreas Kjaer
Andreas Kjaer
MGMatthew Grabowski
Matthew Grabowski
JLJustin Lathia
Justin Lathia
Glioblastoma (GBM) remains a challenging tumor in terms of clinical management, with limited progress made since the standard of care was established in 2005. Maximal safe surgical resection, a cornerstone of the standard-of-care regimen, is a major determinant in patient outcome. However, this key clinical parameter is generally not accounted for in preclinical models, which are often used to provide a rationale for early-phase clinical trials. In this perspective, we cover the current types and status of preclinical GBM resection models and the insights they provide into the GBM disease process. In addition, we discuss how surgical resection alters the immune response, which can affect response to therapies, especially in the context of newly developing and contemporary immunotherapies. Given the complexity of GBM and the use of tumor resection in clinical management, we highlight the necessity and opportunity to integrate surgical resection into preclinical models to help inform and test the next generation of treatments.

2 November 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ALAdam Lauko
Adam Lauko
STSoumya M. Turaga
Soumya M. Turaga
JVJosephine Volovetz
Josephine Volovetz
DBDefne Bayik
Defne Bayik
SBShideng Bao
Shideng Bao
JLJustin Lathia
Justin Lathia
Despite therapeutic interventions for glioblastoma (GBM), self-renewing, therapy-resistant populations of cells referred to as cancer stem cells (CSCs) drive recurrence. Previously, we identified the unique expression of junctional adhesion molecule-A (JAM-A) on CSCs and demonstrated that JAM-A is both necessary and sufficient for self-renewal and tumor growth. Moreover, we determined that JAM-A signals via Akt in GBM CSCs to sustain pluripotency transcription factor activity; however, the entire signaling network has yet to be fully elucidated. To further delineate this pathway, we immunoprecipitated JAM-A from patient-derived GBM CSCs and performed mass spectrometry to determine JAM-A binding proteins. This led to the identification of the cysteine protease inhibitor SerpinB3 as a putative JAM-A binding partner. Using in vitro CSC functional assays, we show that SerpinB3 is necessary for CSC maintenance and survival. In an in vivo orthotopic xenograft model, knockdown of SerpinB3 extended survival. Mechanistically, knockdown of SerpinB3 led to decreased expression of TGF-β, Myc, WNT, and Notch signaling, known regulators of the CSC state. Additionally, knockdown of SerpinB3 increases susceptibility to radiation therapy. SerpinB3 is essential for buffering cells against cathepsin-mediated cell death, and we found that elevated lysosomal membrane permeability after radiation leads to cathepsin release into the cytoplasm. As a result, SerpinB3 knockdown cells have a diminished capacity to inhibit cathepsin-driven cell death after radiation. The addition of the cathepsin inhibitor E64D partially rescues the SerpinB3 knockdown, however, SerpinB3 mutants that are unable to inhibit cathepsins fail to do the same. Taken together, our findings, identify a novel GBM CSC-specific survival mechanism involving a previously uninvestigated cysteine protease inhibitor, SerpinB3, and provide a potential target to increase the efficacy of standard of care GBM therapies against therapy-resistant CSCs.

5 November 2018 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JVJosephine Volovetz
Josephine Volovetz
STSoumya M. Turaga
Soumya M. Turaga
UNUlhas Naik
Ulhas Naik
JLJustin Lathia
Justin Lathia
Cancer stem cells (CSCs) in glioblastoma (GBM), the most lethal primary brain tumor, contribute to tumor progression and therapeutic resistance. While we previously demonstrated that junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is necessary and sufficient for CSC maintenance, the signaling networks underlying this function have yet to be elucidated. JAM-A has several known binding partners in endothelial cells. To identify GBM CSC-specific binding partners, we introduced JAM-A into CSCs, conducted a pull-down assay, and determined binding partners via mass spectrometry. The top candidate identified was Serpin B3, a serine/cysteine proteinase inhibitor and key regulator of epithelial to mesenchymal transition. We validated the endogenous interaction between JAM-A and Serpin B3 via co-immunoprecipitation and confirmed binding dynamics in vitro via surface plasmon resonance. Like JAM-A, Serpin B3 was enriched in CSC patient-derived xenograft models. Immunostaining revealed colocalization of Serpin B3 and JAM-A, in vitro and in vivo. Overexpression of Serpin B3 was found to increase stem cell marker expression. Ongoing studies are assessing proliferation, self-renewal, and tumor initiation in the context of Serpin B3 overexpression in non-CSCs and Serpin B3 knockdown in CSCs. Additional mechanistic studies using JAM-A mutant constructs will determine the precise binding site between JAM-A and Serpin B3 and serve as the basis for developing therapeutics that inhibit the interaction between JAM-A and Serpin B3. Our findings provide a novel JAM-A binding partner and reveal a putative interaction that may be disrupted to compromise CSC maintenance.

21 June 2019
Verified
Book Chapter
Closed access
JVJosephine Volovetz
Josephine Volovetz
DBDefne Bayik
Defne Bayik
JLJustin Lathia
Justin Lathia

5 November 2018 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
TATyler Alban
Tyler Alban
AAAlvaro Alvarado
Alvaro Alvarado
MSMia Dahl Sørensen
Mia Dahl Sørensen
DBDefne Bayik
Defne Bayik
JVJosephine Volovetz
Josephine Volovetz
JLJustin Lathia
Justin Lathia
Therapeutic resistance in glioblastoma (GBM) is linked to cancer stem cells and signaling pathway alterations, but the role of local and systemic immune suppression during disease progression is less understood. To determine how the immune system as a whole is altered in GBM patients, a CyTOF panel of 25 immune markers was developed for immune fingerprinting of peripheral blood mononuclear cells (PBMCs). CyTOF analysis was performed on select patients with either favorable or poor prognosis from a cohort of newly diagnosed GBM patients, from whom PBMCs were collected throughout disease progression. Multi-dimensional cluster analysis identified a reduction of Monocytic Myeloid-Derived Suppressor Cells (M-MDSCs) in the patient with favorable prognosis, while the patient with poor prognosis had higher levels of M-MDSCs. Additionally, when LGG patients were compared to GBM patients, LGG patients had more Dendritic cells and Natural Killer cells as compared to GBM patients. To understand whether this elevation in MDSC was unique to GBM or whether MDSCs were high across primary and secondary brain tumors, a cohort of 259 patient PBMC samples was analyzed. GBM patients had a significant elevation in MDSCs in blood, but not immunosuppressive T regulatory cells as compared to non-malignant brain tumors. To determine whether MDSCs in the GBM microenvironment also correlate with survival, a cohort of patients with matched primary and secondary resections were analyzed for MDSCs by immunofluorescence, which determined that intra-tumoral MDSCs correlate with poor prognosis in recurrent samples, while general myeloid infiltration correlated with a good prognosis. These studies identify low MDSC immune signatures that are linked to enhanced pro-inflammatory cells and overlap between GBM patients with a good prognosis and LGG patients, promoting the idea of targeting MDSCs in GBM patients to alter their immune status to that of a lower grade tumor.

6 February 2019 in Journal of Neurological Surgery Part B: Skull Base
Verified
Conference Paper
Closed access
SCSamantha Colby
Samantha Colby
JJJaes Jones
Jaes Jones
GHGhaith Habboub
Ghaith Habboub
AWAlex Witek
Alex Witek
STShahed Tish
Shahed Tish
PRPablo F. Recinos
Pablo F. Recinos
Introduction: Esthesioneuroblastoma, also referred to as olfactory neuroblastoma, is a rare malignant neoplasm arising from olfactory neuroepithelium. Aiming to provide a comprehensive epidemiologic analysis of esthesioneuroblastomas, this study draws from the Central Brain Tumor Registry of the United States (CBTRUS), which contains population-based incidence data covering 99% of the United States population from 1994 to 2014. Methods: CBTRUS was queried for esthesioneuroblastomas based on ICD-O-3 codes. Age-adjusted incidence per 100,000 persons was calculated and stratified by race, sex, age, lesion location, and diagnostic method. Joinpoint Regression Program was used to calculate annual percentage change in incidence rates over time. Results: A total of 2,103 esthesioneuroblastomas were diagnosed in the United States from 2001 to 2014, averaging ∼150 cases annually. The most common location was the nasal cavity (1709 cases). Those not located in the nasal cavity were found in the ethmoid (182 cases), sphenoid (50 cases), maxillary (39 cases), or accessory sinuses (68 cases). Overall age-adjusted rate was 0.0477 per 100,000 (95% CI, 0.0457–0.0498). There was no statistically significant change in annual rates from 2001 to 2014. A peak rate of 0.1331 per 100,000 (95% CI, 0.1118–0.1571) occurred in patients aged 75–79 years. The rate in males (0.0587 per 100,000; 95% CI, 0.0555–0.0622) was significantly higher (p < 0.05) than in females (0.0013 per 100,000; 95% CI, 0.0354–0.0406). The rate was highest in non-Hispanic white patients at 0.0495 per 100,000 (95% CI, 0.0472–0.0519). The rate ratio of esthesioneuroblastoma in black patients to non-Hispanic white patients was 0.6452 (p < 0.05). There were not enough American Indian/Alaska Native patients to form definitive conclusions. Conclusion: The incidence of esthesioneuroblastomas was higher in males relative to females, and in non-Hispanic white patients relative to black patients. Incidence peaked in patients aged 75 to 79 years. This study represents the most comprehensive epidemiological analysis of esthesioneuroblastoma incidence rate in the United States to date.